Gain Therapeutics (GANX) Assets Average (2021 - 2026)
Gain Therapeutics (GANX) posted quarterly Assets Average of $20.8 million for Q1 2026, up 74.99% year-over-year from $11.9 million in Q1 2025, and up 22.99% quarter-over-quarter from $16.9 million in Q4 2025.
Gain Therapeutics (GANX) Assets Average (2021 - 2026) Analysis & Trends
Gain Therapeutics' Assets Average history runs 6 years deep, the most recent figure standing at $20.8 million for Q1 2026.
- In Q1 2026, Assets Average rose 74.99% year-over-year to $20.8 million; the TTM figure through Mar 2026 stood at $20.8 million (up 74.99% YoY), while the FY2025 annual figure was $17.5 million, up 13.7% from the prior year.
- Assets Average for Q1 2026 stood at $20.8 million, up from $16.9 million in the prior quarter.
- The five-year high for Assets Average was $38.3 million in Q1 2022, with the low at $10.4 million in Q3 2025.
- The 5-year median for Assets Average is $16.9 million (2024), against an average of $19.9 million.
- The sharpest annual moves came in 2023 and 2026: Assets Average slumped 46.26% in 2023, then soared 74.99% in 2026.
- Gain Therapeutics' Assets Average stood at $26.2 million in 2022, then plunged by 37.61% to $16.4 million in 2023, then declined by 19.01% to $13.2 million in 2024, then increased by 27.56% to $16.9 million in 2025, then climbed by 22.99% to $20.8 million in 2026.
- Business Quant data shows GANX's Assets Average at $20.8 million in Q1 2026, $16.9 million in Q4 2025, and $10.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Gain Therapeutics | 85.12 Mn | 85.12 Mn | - | 17.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.08 Mn |
| Mar 31, 2026 | 20.78 Mn |
| Dec 31, 2025 | 16.90 Mn |
| Sep 30, 2025 | 10.40 Mn |
| Jun 30, 2025 | 10.73 Mn |
| Mar 31, 2025 | 11.87 Mn |
| Dec 31, 2024 | 13.24 Mn |
| Sep 30, 2024 | 16.78 Mn |
| Jun 30, 2024 | 16.89 Mn |
| Mar 31, 2024 | 16.59 Mn |
| Dec 31, 2023 | 16.35 Mn |
| Sep 30, 2023 | 16.18 Mn |
| Jun 30, 2023 | 19.79 Mn |
| Mar 31, 2023 | 22.71 Mn |
| Dec 31, 2022 | 26.21 Mn |
| Sep 30, 2022 | 30.11 Mn |
| Jun 30, 2022 | 34.74 Mn |
| Mar 31, 2022 | 38.29 Mn |
| Dec 31, 2021 | 40.77 Mn |
| Sep 30, 2021 | 43.96 Mn |